RO.CH

329.2

+0.67%↑

NOVN.CH

120.42

-0.27%↓

LONN.CH

528.8

+2.2%↑

SDZ.CH

67.3

+1.97%↑

STMN.CH

87.58

+3.6%↑

RO.CH

329.2

+0.67%↑

NOVN.CH

120.42

-0.27%↓

LONN.CH

528.8

+2.2%↑

SDZ.CH

67.3

+1.97%↑

STMN.CH

87.58

+3.6%↑

RO.CH

329.2

+0.67%↑

NOVN.CH

120.42

-0.27%↓

LONN.CH

528.8

+2.2%↑

SDZ.CH

67.3

+1.97%↑

STMN.CH

87.58

+3.6%↑

RO.CH

329.2

+0.67%↑

NOVN.CH

120.42

-0.27%↓

LONN.CH

528.8

+2.2%↑

SDZ.CH

67.3

+1.97%↑

STMN.CH

87.58

+3.6%↑

RO.CH

329.2

+0.67%↑

NOVN.CH

120.42

-0.27%↓

LONN.CH

528.8

+2.2%↑

SDZ.CH

67.3

+1.97%↑

STMN.CH

87.58

+3.6%↑

Home・Aandelen Lijst・Bachem Holding AG

Bachem Holding AG

Gesloten

SectorGezondheidszorg

73.75 5.28

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

69.9

Max

74.1

Belangrijke statistieken
By Trading Economics
Inkomsten	49M 99M
Verkoop	69M 382M
K/W Sectorgemiddelde	33.51 66.418
Dividendrendement	1.35
Winstmarge	25.83
Werknemers	2,130
EBITDA	35M 107M

Aanbevelingen
By TipRanks
Aanbevelingen	Strong Buy
12 Maanden Prognose	+20.63% upside

Dividenden
By Dow Jones
Dividendrendement Sectorgemiddelde	1.35% 2.36%

Marktinformatie
By TradingEconomics
Marktkapitalisatie	901M 5B
Vorige openingsprijs	68.47
Vorige sluitingsprijs	73.75

Nieuwssentiment

By Acuity

50%

154 / 348 Rangschikking in Healthcare

Bachem Holding AG Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

13 apr 2026, 23:25 UTC

Belangrijke Nieuwsgebeurtenissen

Westpac Expects Higher Loan Losses as Iran Conflict Slows Australian Economy -- Update

13 apr 2026, 22:45 UTC

Belangrijke Nieuwsgebeurtenissen

Westpac Expects Higher Loan Losses as Iran Conflict Slows Australian Economy

13 apr 2026, 18:03 UTC

Winsten

Louis Vuitton Owner Logs Weak Sales as Middle East War Takes Toll -- 2nd Update

13 apr 2026, 23:58 UTC

Winsten

Review & Preview: Earnings Time -- Barrons.com

13 apr 2026, 23:49 UTC

Marktinformatie

Nikkei May Rise After Overnight Gains on Wall Street -- Market Talk

13 apr 2026, 23:33 UTC

Marktinformatie

Belangrijke Nieuwsgebeurtenissen

Gold Edges Higher Amid Dollar Weakness -- Market Talk

13 apr 2026, 23:20 UTC

Marktinformatie

Uranium Stocks Seen Benefiting From Energy Security Concerns -- Market Talk

13 apr 2026, 23:01 UTC

Winsten

Aura: Capex Guidance Revised From $111M and $130M to New Range of $262M and $314M >AURA33.SA.BR

13 apr 2026, 23:01 UTC

Winsten

Aura Minerals: Announces Update to Capex Guidance Including Construction of the Era Dorada Project

13 apr 2026, 23:01 UTC

Winsten

Aura: Will Update Cap Expenditure Guidance to Include the Project's Construction Phase >AURA33.SA.BR

13 apr 2026, 22:21 UTC

Acquisities, Fusies, Overnames

Chevron Swaps Offshore Gas Stakes to Boost Venezuelan Heavy-Oil Footprint -- Update

13 apr 2026, 21:53 UTC

Winsten

MarketWise, Inc.: Affirms FY 2026 Guidance, Including Div Target to Class A Hldrs of $1.80 per Shr

13 apr 2026, 21:53 UTC

Winsten

MarketWise, Inc.: Paid Subscribers Were 381,000 at March 31 Compared to 374,000 at Dec 31, 2025, Active Free Subscribers Were 2.0M at March 31 >MKTW

13 apr 2026, 21:53 UTC

Winsten

MarketWise, Inc.: 1Q Billings Increased Approximately 15% Yr-over-Yr to Approximately $81M

13 apr 2026, 21:53 UTC

Winsten

MarketWise, Inc.: Preliminary Selected Unaudited 1Q Paid Subscribers Returning to Growth

13 apr 2026, 21:26 UTC

Belangrijke Nieuwsgebeurtenissen

U.S. Oil Blockade Is Set to Boost American Exports -- and Prices at the Pump -- WSJ

13 apr 2026, 21:23 UTC

Winsten

Johnson & Johnson Earnings: Oncology Powers Growth, but Talc Lawsuits Persist -- Barrons.com

13 apr 2026, 21:16 UTC

Winsten

Goldman Sachs Reports Record Quarter in Banking and Trading -- 4th Update

13 apr 2026, 20:50 UTC

Marktinformatie

Belangrijke Nieuwsgebeurtenissen

Basic Materials Roundup: Market Talk

13 apr 2026, 20:50 UTC

Marktinformatie

Auto & Transport Roundup: Market Talk

13 apr 2026, 20:34 UTC

Winsten

Victory Capital: 1Q Long-Term AUM Net Flows of -$457M >VCTR

13 apr 2026, 20:34 UTC

Winsten

Victory Capital: March Avg Total AUM Was $315.3B, Avg Other Assets $3.2B, Avg Total Client Assets $318.5B >VCTR

13 apr 2026, 20:34 UTC

Winsten

Victory Capital Holdings, Inc.: Total Assets Under Management of $309.8B, Other Assets $3.3B, Total Client Assets of $313.1B as of March 31 >VCTR

13 apr 2026, 19:59 UTC

Marktinformatie

Canada Consumers Sour Prior to Big Energy-Price Jump -- Market Talk

13 apr 2026, 19:50 UTC

Marktinformatie

Belangrijke Nieuwsgebeurtenissen

Oil Futures Pull Back From Highs on Hopes for Talks -- Market Talk

13 apr 2026, 19:27 UTC

Marktinformatie

Belangrijke Nieuwsgebeurtenissen

Correction to Precious Metals Market Talk on April 9

13 apr 2026, 19:14 UTC

Marktinformatie

U.S. Natural Gas Futures Settle Lower on Mild Weather -- Market Talk

13 apr 2026, 18:59 UTC

Marktinformatie

Belangrijke Nieuwsgebeurtenissen

Fed's Goolsbee: Don't Be Surprised If Consumer Confidence Sours -- Market Talk

13 apr 2026, 18:59 UTC

Marktinformatie

Belangrijke Nieuwsgebeurtenissen

Fed's Goolsbee: Oil Shows People Expect Short Term Conflict in Iran -- Market Talk

13 apr 2026, 18:43 UTC

Marktinformatie

Precious Metals Lose Ground as U.S. Blockade in Hormuz Gets Underway -- Market Talk

Peer Vergelijking

Prijswijziging

Bachem Holding AG Prognose

Koersdoel

By TipRanks

20.63% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 84.2 CHF 20.63%

Hoogste 110 CHF

Laagste 65 CHF

Gebaseerd op 5 Wall Street-analisten die 12-maands prijsdoelen bieden voor Bachem Holding AG - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

5 ratings

Buy

Hold

Sell

Gebaseerd op 5 analisten die aandelenratings hebben gegeven aan Bachem Holding AG - Dist in de afgelopen 3 maanden.

Sentiment

By Acuity

154 / 348 Rangschikking in Gezondheidszorg

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Bachem Holding AG

Bachem Holding AG, together with its subsidiaries, provides products for research, clinical development, and commercial application to pharmaceutical and biotechnology companies worldwide. The company engages in the development, production, and regulatory support of peptide active pharmaceutical ingredients, such as peptide and oligonucleotide new chemical entities (NCEs). It also offers commercial NCEs and generics; and project management, quality and regulatory, analytical, good manufacturing practice production, research grade production, and supply and vertical integration services. Bachem Holding AG was founded in 1971 and is headquartered in Bubendorf, Switzerland.